Shingles vaccine, Shingrix, receives approval in Canada
by Press Release from Outbreak News Today on (#35388)
GlaxoSmithKline announced Friday that Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged 50 years or older. Shingrix is a non-live, recombinant subunit adjuvanted vaccine given intramuscularly in two doses. Shingles is caused by reactivation of the varicella zoster virus, the same virus that causes chickenpox. A person's risk ["]
The post Shingles vaccine, Shingrix, receives approval in Canada appeared first on Outbreak News Today.